Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,038 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype.
Thornhill JP, Pace M, Martin GE, Hoare J, Peake S, Herrera C, Phetsouphanh C, Meyerowitz J, Hopkins E, Brown H, Dunn P, Olejniczak N, Willberg C, Klenerman P, Goldin R, Fox J, Fidler S, Frater J; CHERUB investigators. Thornhill JP, et al. Among authors: herrera c. Mucosal Immunol. 2019 Sep;12(5):1212-1219. doi: 10.1038/s41385-019-0180-2. Epub 2019 Jun 25. Mucosal Immunol. 2019. PMID: 31239514 Free article.
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Fox J, Tiraboschi JM, Herrera C, Else L, Egan D, Dickinson L, Jackson A, Olejniczak N, Back D, Khoo S, Shattock R, Boffito M. Fox J, et al. Among authors: herrera c. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):252-257. doi: 10.1097/QAI.0000000000001108. J Acquir Immune Defic Syndr. 2016. PMID: 27727157 Clinical Trial.
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).
Herrera C, Lwanga J, Lee M, Mantori S, Amara A, Else L, Penchala SD, Egan D, Challenger E, Dickinson L, Boffito M, Shattock R, Khoo S, Fox J. Herrera C, et al. J Antimicrob Chemother. 2021 Jul 15;76(8):2129-2136. doi: 10.1093/jac/dkab136. J Antimicrob Chemother. 2021. PMID: 33993302 Free PMC article. Clinical Trial.
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.
Karim QA, Archary D, Barré-Sinoussi F, Broliden K, Cabrera C, Chiodi F, Fidler SJ, Gengiah TN, Herrera C, Kharsany ABM, Liebenberg LJP, Mahomed S, Menu E, Moog C, Scarlatti G, Seddiki N, Sivro A, Cavarelli M. Karim QA, et al. Among authors: herrera c. Front Immunol. 2022 Dec 6;13:1055042. doi: 10.3389/fimmu.2022.1055042. eCollection 2022. Front Immunol. 2022. PMID: 36561760 Free PMC article. Review.
HIV-1 CNS in vitro infectivity models based on clinical CSF samples.
Mora-Peris B, Winston A, Garvey L, Else LJ, Shattock RJ, Herrera C. Mora-Peris B, et al. Among authors: herrera c. J Antimicrob Chemother. 2016 Jan;71(1):235-43. doi: 10.1093/jac/dkv326. Epub 2015 Oct 15. J Antimicrob Chemother. 2016. PMID: 26472771 Free PMC article.
1,038 results